慢性乙型肝炎患者肝组织基质金属蛋白酶组织抑制物-1表达及其意义*

doi:10.3969/j.issn.1672-5069.2014.03.007

Abstract

Abstract: Objective To evaluate the expression of tissue inhibitor of metalloproteinases-1 （TIMP-1） in livers of patients with chronic hepatitis B（CHB） and to explore the potential relationship between TIMP-1 level and hepatic fibrosis progression. Methods The tissue and serum levels of TIMP-1 were determined by immunohistochemistry and double-antibody sandwich enzyme-linked immunoadsorbent assay,respectively,and their correlation was determined. One hundred and fifty-nine patients with CHB underwent liver biopsy and their liver histological activity index （HAI） and fibrosis （S） were determined. The correlation between the serum TIMP-1 levels and HAI grading and staging was analyzed. Results The expression of TIMP-1 in liver tissues were positively correlated to serum TIMP-1 levels in CHB patients （r=0.9521,P<0.01）;Serum TIMP-1 levels were significant different among patients with different liver fibrosis stages（S₁ to S₄）（P<0.05）,and a positive correlation between serum TIMP-1 level and hepatic fibrosis staging was found（r=0.704,P<0.01）;However,there were no significant differences in serum TIMP-1 levels among patients with different liver inflammatory grades. ConclusionsSerum TIMP-1 level is not affected by liver inflammatory grades and is promising in non-invasive clinical evaluation of liver fibrosis.

Key words: Chronic hepatitis B, Tissue inhibitor of metalloproteinases-1, Hepatic fibrosis, Inflammation

Zhu Chuanlong, Li Yuwen, Li Wenting. Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 245-249.

References

[1] Boeker KH,Haberkorn CI,Michels D,et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta,2002,316（1-2）:71-81.
[2] Lichtinghagen R,Pietsch D,Bantel H,et al. The enhanced liver fibrosis（ELF） score:normal values,influence factors and proposed cut-off values. J Hepatol,2013,59（2）:236-242.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[4] Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol,2003,38（3）:357-360.
[5] Torok NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol,2008,43（5）:315-321.
[6] Gagliano N,Arosio B,Grizzi F,et al. Reduced collagenolytic activity of matrix metalloproteinases and development of liver fibrosis in the aging rat. Mech Ageing Dev,2002,123:413-425.
[7] Watanabe T,Niioka M,Ishikawa A,et al. Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat. J Hepatol,2001,35:465-473.
[8] Lichtinghagen R,Michels D,Haberkorn CI,et al. Matrix metalloproteinase（MMP）-2,MMP-7,and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C.J Hepatol,2001,34:239-247.
[9] Yoshiji H,Kuriyama S,Miyamoto Y,et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology,2000,32:1248-1254.
[10] Vaillant B,Chiaramonte MG,Cheever AW,et al. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol,2001,167:7017-7026.
[11] McCrudden R,Iredale JP. Liver fibrosis,the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000,15:1159-1168.
[12] Ueno T,Tamaki S,Sugawara H,et al. Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases.J Hepatol,1996,24:177-184.
[13] Nie QH,Zhu CL,Zhang YF,et al. Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci,2010,55:1286-1295.
[14] Boker KH, Pehle B,Steinmetz C,et al. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis.Hepatogastroenterology,2000,47（33）:812-819.
[15] Heymans S, Schroen B,Vermeersch P,et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation,2005,112（8）:1136-1144.
[16] Sam L,Nicolas R,Brain GO,et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Am J Respir Crit Care Med,2000,162（4）:1355-1360.
[17] Jenny TM,Donald PT, Paula NB, et al. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest,2003,124:1724-1732.
[18] Ruiz V,Ordonez RM,Berumen J, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol,2003,285（5）:L1026-1036.
[19] Nee LE,McMorrow T,Campbell E,et al. TNF-alpha and IL-1beta-mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int,2004,66（4）:1376-1386.
[20] Chevalier RL. Pathogenesis of renal injury in obstructive uropathy. Curr Opin Pediatr,2006,18（2）:153-160.
[21] Murawaki Y,Ikuta Y,Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases（TIMP）-2 assay in patients with chronic liver disease in comparison with serum TIMP-1.Clin Chim Acta,1999,281（1-2）:109-120.

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[7]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[8]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[9]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[10]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[11]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[12]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[13]	Liu Enqiang, Chen Guo, Liao Xiuyong, et al.. Inhibition of TGF-β1/Smad/ERK passway by astaxanthin in rats with CCl₄-induced liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 842-846.
[14]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[15]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.